Key Highlights

  • AlgoraeRx executed a non-binding Memorandum of Understanding and a separate, binding Licence and Supply Agreement with Umedica Laboratories.
  • Under the MOU, AlgoraeRx is appointed exclusive importer, distributor and commercial partner in Australia across eight molecules, limited to Umedica-branded products.
  • The dossier for the product covered by the Licence and Supply Agreement has been submitted to the Therapeutic Goods Administration.
  • The financial terms of the Licence and Supply Agreement are commercial-in-confidence.

Algorae Pharmaceuticals Ltd (ASX:1AI) announced on 19 October 2026 that its wholly owned subsidiary, AlgoraeRx Pty Ltd, has entered two separate agreements with Umedica Laboratories Pvt. Limited for the Australian market. One is a non-binding Memorandum of Understanding (MOU) and the other is a binding Licence and Supply Agreement (LSA).

The non-binding MOU

Under the MOU, AlgoraeRx is appointed as Umedica’s exclusive importer, distributor and commercial partner in Australia across a portfolio of eight molecules. Umedica acts as the manufacturer and Marketing Authorisation Holder. The exclusivity applies specifically to Umedica-branded, or sponsored, products only.

The MOU sets out the framework for the collaboration. Because it is non-binding, definitive agreements remain to be negotiated, and the announcement said this will take place in due course.

The binding Licence and Supply Agreement

The LSA is a standalone licence and supply arrangement. Umedica licenses its dossier and know-how and will supply the product. AlgoraeRx will obtain the marketing authorisation and commercialise the product under its own brand in Australia.

The dossier for the LSA product has been submitted to the Therapeutic Goods Administration (TGA) for regulatory approval, and the outcome of that submission was not reported. Further molecules are under evaluation for additional licence and supply arrangements. The financial terms of the LSA are commercial-in-confidence, so the announcement did not disclose payment amounts, volumes or timing.

About Umedica Laboratories

Umedica is a vertically integrated Indian pharmaceutical company headquartered in Mumbai. It manufactures active pharmaceutical ingredients (APIs) through its API arm, Amoli Organics, and produces finished dosage forms in-house. Both its API and finished-product plants are approved by the United States Food and Drug Administration, the European Union, the United Kingdom, the TGA and Health Canada.

About Algorae and AlgoraeRx

Algorae describes itself as an AI-enabled pharmaceutical company with two areas of focus: drug-combination discovery and pharmaceutical commercialisation. Its proprietary platform, AlgoraeOS, applies machine learning and deep neural networks to identify synergistic drug combinations and guide dose selection for preclinical development.

AlgoraeRx is the company’s commercialisation business. It sources, licenses and supplies generic and specialty medicines in Australia and New Zealand through partnered manufacturers and established distribution channels. Algorae also states that it works with research institutions and industry partners to translate AI-predicted therapies and expand patient access to medicines.

Forward-looking statement factors

The release carries a forward-looking statements notice. It lists factors that could cause outcomes to differ, including regulatory approvals and actions of the TGA and other authorities, commercial, distribution and supply arrangements, competition, funding and access to capital, pricing and reimbursement pressures, and counterparty and partnership risks. Algorae said it will update shareholders as the initiatives progress.